Jiangsu Hualan New Pharmaceutical Material Co.,Ltd.

SZSE:301093 Stock Report

Market Cap: CN¥2.9b

Jiangsu Hualan New Pharmaceutical MaterialLtd Past Earnings Performance

Past criteria checks 2/6

Jiangsu Hualan New Pharmaceutical MaterialLtd's earnings have been declining at an average annual rate of -5.3%, while the Medical Equipment industry saw earnings growing at 8% annually. Revenues have been declining at an average rate of 4.1% per year. Jiangsu Hualan New Pharmaceutical MaterialLtd's return on equity is 4.1%, and it has net margins of 16.1%.

Key information

-5.3%

Earnings growth rate

-13.8%

EPS growth rate

Medical Equipment Industry Growth16.0%
Revenue growth rate-4.1%
Return on equity4.1%
Net Margin16.1%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Jiangsu Hualan New Pharmaceutical MaterialLtd makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:301093 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 245939514639
31 Dec 2362311814436
30 Sep 2363110616136
30 Jun 236199815537
31 Mar 236109614836
01 Jan 235849414137
30 Sep 2258610813239
30 Jun 2269116413541
31 Mar 2278420614244
01 Jan 2282121614442
30 Sep 2178421412237
30 Jun 2163315110831
31 Mar 215091038825
31 Dec 20446817724
31 Dec 19460958920
31 Dec 18434867921
31 Dec 17388776816

Quality Earnings: 301093 has high quality earnings.

Growing Profit Margin: 301093's current net profit margins (16.1%) are higher than last year (15.7%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 301093's earnings have declined by 5.3% per year over the past 5 years.

Accelerating Growth: 301093's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 301093 had negative earnings growth (-0.5%) over the past year, making it difficult to compare to the Medical Equipment industry average (-1.3%).


Return on Equity

High ROE: 301093's Return on Equity (4.1%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.